NVO:NYE-Novo Nordisk A/S (USD)

EQUITY | Biotechnology | New York Stock Exchange

Last Closing

USD 125.26

Change

+2.55 (+2.08)%

Market Cap

USD 81.07B

Volume

3.80M

Analyst Target

USD 70.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

-0.28 (-0.70%)

USD 3.55B
HTD John Hancock Tax Advantaged Di..

+0.21 (+1.07%)

USD 2.41B
DNA Ginkgo Bioworks Holdings

+0.02 (+2.26%)

USD 2.17B
RCUS Arcus Biosciences Inc

N/A

USD 1.41B
NUVB Nuvation Bio Inc

+0.07 (+2.19%)

USD 0.64B
ADCT ADC Therapeutics SA

+0.02 (+0.42%)

USD 0.39B
PGP PIMCO Global StocksPLUS & Inco..

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.29B
LCTX Lineage Cell Therapeutics Inc

-0.08 (-7.08%)

USD 0.28B
ATNM Actinium Pharmaceuticals Inc

+0.97 (+12.47%)

USD 0.23B

ETFs Containing NVO

PPH VanEck Pharmaceutical ETF 9.83 % 0.36 %

-0.55 (0%)

USD 0.49B
PJIO Pgim ETF Trust - Jennison.. 6.95 % 0.00 %

+0.49 (+0%)

USD 0.01B
LIFE-U:CA Evolve Global Healthcare .. 5.68 % 0.00 %

+0.01 (+0%)

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.58 % 0.00 %

-0.10 (0%)

CAD 0.01B
PJBF 4.53 % 0.00 %

N/A

N/A
FPXI First Trust International.. 4.25 % 0.70 %

+0.71 (+0%)

USD 0.15B
SPWO S&P World ETF 3.51 % 0.00 %

+0.03 (+0%)

USD 0.01B
AVSD American Century ETF Trus.. 1.65 % 0.00 %

+0.70 (+0%)

USD 0.13B
HAZ:CA Global X Active Global Di.. 0.00 % 0.94 %

-0.08 (0%)

CAD 0.35B
HFXI IQ 50 Percent Hedged FTSE.. 0.00 % 0.20 %

+0.28 (+0%)

USD 0.55B
JPIN JPMorgan Diversified Retu.. 0.00 % 0.40 %

+0.92 (+0%)

USD 0.37B
RFAP 0.00 % 0.83 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

-0.02 (0%)

CAD 0.05B
PTIN Pacer Trendpilot Internat.. 0.00 % 0.00 %

+0.41 (+0%)

USD 0.15B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 0.00 %

+0.51 (+0%)

USD 0.03B
PDEV 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
TLTD FlexShares Morningstar De.. 0.00 % 0.39 %

+0.91 (+0%)

USD 0.51B
DMRI 0.00 % 0.50 %

N/A

N/A
IMEA:LSE 0.00 % 0.00 %

N/A

N/A
BKIE BNY Mellon International .. 0.00 % 0.00 %

+0.86 (+0%)

USD 0.60B
GINN Goldman Sachs Innovate Eq.. 0.00 % 0.00 %

+1.06 (+0%)

USD 0.33B
LEAD-U:CA Evolve Future Leadership .. 0.00 % 0.00 %

N/A

CAD 0.02B
NTSI WisdomTree International .. 0.00 % 0.00 %

+0.47 (+0%)

USD 0.32B
LEAD-B:CA Evolve Future Leadership .. 0.00 % 0.00 %

N/A

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.08% 81% B- 94% A
Dividend Return 0.64% 20% F 35% F
Total Return 21.72% 81% B- 94% A
Trailing 12 Months  
Capital Gain 46.95% 85% B 93% A
Dividend Return 1.30% 20% F 17% F
Total Return 48.25% 85% B 92% A
Trailing 5 Years  
Capital Gain 417.92% 90% A- 98% N/A
Dividend Return 16.24% 20% F 63% D
Total Return 434.17% 90% A- 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.80% 88% B+ 93% A
Dividend Return 40.67% 88% B+ 93% A
Total Return 1.87% 20% F 44% F
Risk Return Profile  
Volatility (Standard Deviation) 23.19% 88% B+ 49% F
Risk Adjusted Return 175.36% 100% F 100% F
Market Capitalization 81.07B 100% F 100% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.90 7% 13%
Price/Book Ratio 36.27 6% 2%
Price / Cash Flow Ratio 5.16 3% 59%
Price/Free Cash Flow Ratio 4.90 8% 65%
Management Effectiveness  
Return on Equity 88.07% 100% 98%
Return on Invested Capital 70.15% 92% 98%
Return on Assets 23.39% 100% 99%
Debt to Equity Ratio 14.99% 33% 84%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.